Jump to content
Linus

Opinion: The New Ketamine-Based Antidepressant Is a Rip-Off

Recommended Posts

Linus

It was no better than placebo in two of the three short-term Phase-III studies submitted to the FDA for approval.

 

But the biggest problem at hand is not the drug itself. It’s the fact that instead of representing a revolution in mental health treatment, as it has been touted to do, esketamine is not a breakthrough at all. It’s just a way for pharmaceutical company Johnson & Johnson to make a significant profit off gullible insurance companies and vulnerable patients.

 

https://www.vice.com/en_us/article/pajkjy/opinion-the-new-ketamine-based-antidepressant-is-a-rip-off?fbclid=IwAR2HdQjDaaGdn2rvIwtPdllr0czgUYm8ES8fyX6NcyQAiZiqLDemZIxcwjk

Share this post


Link to post
Share on other sites
Rosetta

Not to mention the negative effects and downsides which undoubtedly have been hidden, downplayed and outright denied.  At $900 a dose and $7,000 for the first month of treatment let's hope very few people have the "opportunity" to be "helped" by this new drug.  After what has happened with fosamax, Vioxxx, oxycontin and all the benzos as well as the ADs, I don't trust the pharmaceutical companies with regard to anything at all. 

Share this post


Link to post
Share on other sites

Please sign in to comment

You will be able to leave a comment after signing in



Sign In Now

×
×
  • Create New...

Important Information

Terms of Use Privacy Policy